Share Price and Basic Stock Data
Last Updated: February 7, 2026, 7:13 pm
| PEG Ratio | -2.24 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Tata Chemicals Ltd operates in the inorganic chemicals sector, focusing on caustic soda and soda ash. The company’s price stood at ₹727, with a market capitalization of ₹18,507 Cr. In the latest financial year ending March 2023, Tata Chemicals reported sales of ₹16,789 Cr, a substantial increase from ₹12,622 Cr in March 2022. However, sales have shown variability in the recent quarters, with the latest quarter (Sep 2023) recording ₹3,998 Cr, down from ₹4,407 Cr in Mar 2023. The sales trend indicates fluctuations, with a notable decline observed in the latter half of 2023, raising questions about demand stability. The operating profit margin (OPM) for FY 2025 is projected to be 13%, down from 23% in FY 2023, reflecting a tightening in profit margins likely due to rising input costs and competitive pressures. The company’s performance can be seen as aligned with the broader chemical industry trends, where demand dynamics can significantly influence revenue outcomes.
Profitability and Efficiency Metrics
Tata Chemicals’ profitability metrics indicate a challenging environment, with a net profit of ₹400 Cr for the latest fiscal year. This figure represents a decrease from the ₹2,434 Cr profit reported in FY 2023, illustrating significant pressures on profitability. The company’s return on equity (ROE) stood at 1.20%, while return on capital employed (ROCE) was at 3.96%, both of which are relatively low compared to typical sector averages. The operating profit was ₹2,847 Cr for FY 2024, with a corresponding OPM of 18%. The interest coverage ratio (ICR) of 3.87x reflects the company’s ability to meet interest obligations, but this level of coverage is typically seen as adequate rather than strong. The cash conversion cycle (CCC) of 53 days indicates that the company is managing its operational efficiency moderately well, although there is room for improvement in receivables and inventory management.
Balance Sheet Strength and Financial Ratios
The balance sheet of Tata Chemicals reveals a total debt of ₹7,495 Cr against reserves of ₹22,103 Cr, showcasing a relatively healthy leverage position with a debt-to-equity ratio of 0.29. This suggests that the company is not overly reliant on debt for financing its operations. However, the interest expense has increased, with ₹563 Cr reported for FY 2025, which could strain future profitability. The company’s current ratio is 1.09, indicating it possesses adequate short-term liquidity to meet its obligations. The book value per share stood at ₹846.82 as of March 2025, which reflects the intrinsic value of the company’s equity. Nonetheless, the declining trend in return on capital employed (ROCE) to 4% for FY 2025, down from 10.43% in FY 2023, raises concerns about the efficiency of capital utilization. Overall, while the balance sheet is relatively stable, the declining profitability metrics indicate potential challenges ahead.
Shareholding Pattern and Investor Confidence
The shareholding structure of Tata Chemicals reveals a stable promoter holding of 37.98%, which has remained consistent over the recent quarters. Institutional investors, including foreign institutional investors (FIIs) and domestic institutional investors (DIIs), hold 13.73% and 22.17% of the company, respectively. This indicates a healthy level of institutional interest, reflecting confidence in the company’s long-term prospects. The number of public shareholders stood at 6,50,693, showing a slight decline from previous quarters. The presence of institutional investors suggests that Tata Chemicals is viewed favorably in the market, despite recent profitability challenges. However, the fluctuations in the stock price and investor sentiment can create volatility in the share price, impacting investor confidence. Overall, the stable promoter stake combined with institutional support provides a foundation for potential recovery, albeit with caution warranted due to recent performance metrics.
Outlook, Risks, and Final Insight
Looking ahead, Tata Chemicals faces both opportunities and risks. On one hand, the company is well-positioned to benefit from the growing demand for inorganic chemicals, particularly in the context of sustainability initiatives. However, significant risks remain, including rising raw material costs and increased competition, which could further pressure margins. The company’s ability to navigate these challenges while maintaining operational efficiency will be critical. The recent decline in sales and profitability metrics may signal a need for strategic adjustments, particularly in cost management and market positioning. If demand stabilizes and input costs are managed effectively, there is potential for recovery in profitability. Conversely, continued margin compression could lead to a more prolonged period of underperformance. Investors should remain vigilant regarding these dynamics as the company strives to enhance its operational and financial performance.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Caprolactam Chemicals Ltd | 32.1 Cr. | 69.7 | 81.0/37.5 | 3,207 | 11.6 | 0.00 % | 0.48 % | 13.7 % | 10.0 |
| Standard Industries Ltd | 101 Cr. | 15.7 | 25.5/13.0 | 20.4 | 0.00 % | 7.81 % | 10.5 % | 5.00 | |
| Gujarat Alkalies & Chemicals Ltd | 3,471 Cr. | 473 | 700/418 | 759 | 3.34 % | 0.34 % | 1.13 % | 10.0 | |
| GHCL Ltd | 4,717 Cr. | 513 | 713/500 | 9.30 | 396 | 2.34 % | 24.2 % | 18.6 % | 10.0 |
| Tata Chemicals Ltd | 17,933 Cr. | 704 | 1,027/692 | 65.9 | 877 | 1.56 % | 3.96 % | 1.20 % | 10.0 |
| Industry Average | 5,359.40 Cr | 362.57 | 835.10 | 392.00 | 1.26% | 7.11% | 8.14% | 9.17 |
Quarterly Result
| Metric | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 4,148 | 4,407 | 4,218 | 3,998 | 3,730 | 3,475 | 3,789 | 3,999 | 3,590 | 3,509 | 3,719 | 3,877 | 3,550 |
| Expenses | 3,317 | 3,442 | 3,175 | 3,191 | 3,188 | 3,032 | 3,215 | 3,381 | 3,156 | 3,182 | 3,070 | 3,340 | 3,205 |
| Operating Profit | 831 | 965 | 1,043 | 807 | 542 | 443 | 574 | 618 | 434 | 327 | 649 | 537 | 345 |
| OPM % | 20% | 22% | 25% | 20% | 15% | 13% | 15% | 15% | 12% | 9% | 17% | 14% | 10% |
| Other Income | 30 | 86 | 67 | 187 | 98 | -861 | 116 | 152 | -10 | 29 | 138 | 128 | 21 |
| Interest | 107 | 133 | 123 | 145 | 132 | 130 | 133 | 145 | 148 | 137 | 147 | 144 | 146 |
| Depreciation | 227 | 234 | 229 | 234 | 246 | 271 | 273 | 277 | 280 | 293 | 280 | 285 | 293 |
| Profit before tax | 527 | 684 | 758 | 615 | 262 | -819 | 284 | 348 | -4 | -74 | 360 | 236 | -73 |
| Tax % | 19% | -1% | 23% | 20% | 26% | 3% | 33% | 23% | 425% | -34% | 12% | 35% | -5% |
| Net Profit | 425 | 692 | 587 | 495 | 194 | -841 | 190 | 267 | -21 | -49 | 316 | 154 | -69 |
| EPS in Rs | 15.35 | 27.83 | 20.88 | 16.80 | 6.20 | -33.36 | 5.89 | 7.61 | -2.08 | -2.20 | 9.89 | 3.02 | -3.65 |
Last Updated: February 6, 2026, 12:46 am
Below is a detailed analysis of the quarterly data for Tata Chemicals Ltd based on the most recent figures (Dec 2025) and their trends compared to the previous period:
- For Sales, as of Dec 2025, the value is 3,550.00 Cr.. The value appears to be declining and may need further review. It has decreased from 3,877.00 Cr. (Sep 2025) to 3,550.00 Cr., marking a decrease of 327.00 Cr..
- For Expenses, as of Dec 2025, the value is 3,205.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 3,340.00 Cr. (Sep 2025) to 3,205.00 Cr., marking a decrease of 135.00 Cr..
- For Operating Profit, as of Dec 2025, the value is 345.00 Cr.. The value appears to be declining and may need further review. It has decreased from 537.00 Cr. (Sep 2025) to 345.00 Cr., marking a decrease of 192.00 Cr..
- For OPM %, as of Dec 2025, the value is 10.00%. The value appears to be declining and may need further review. It has decreased from 14.00% (Sep 2025) to 10.00%, marking a decrease of 4.00%.
- For Other Income, as of Dec 2025, the value is 21.00 Cr.. The value appears to be declining and may need further review. It has decreased from 128.00 Cr. (Sep 2025) to 21.00 Cr., marking a decrease of 107.00 Cr..
- For Interest, as of Dec 2025, the value is 146.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 144.00 Cr. (Sep 2025) to 146.00 Cr., marking an increase of 2.00 Cr..
- For Depreciation, as of Dec 2025, the value is 293.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 285.00 Cr. (Sep 2025) to 293.00 Cr., marking an increase of 8.00 Cr..
- For Profit before tax, as of Dec 2025, the value is -73.00 Cr.. The value appears to be declining and may need further review. It has decreased from 236.00 Cr. (Sep 2025) to -73.00 Cr., marking a decrease of 309.00 Cr..
- For Tax %, as of Dec 2025, the value is -5.00%. The value appears to be improving (decreasing) as expected. It has decreased from 35.00% (Sep 2025) to -5.00%, marking a decrease of 40.00%.
- For Net Profit, as of Dec 2025, the value is -69.00 Cr.. The value appears to be declining and may need further review. It has decreased from 154.00 Cr. (Sep 2025) to -69.00 Cr., marking a decrease of 223.00 Cr..
- For EPS in Rs, as of Dec 2025, the value is -3.65. The value appears to be declining and may need further review. It has decreased from 3.02 (Sep 2025) to -3.65, marking a decrease of 6.67.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:22 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 15,885 | 17,204 | 14,873 | 10,346 | 10,270 | 10,337 | 10,357 | 10,200 | 12,622 | 16,789 | 15,421 | 14,887 | 14,695 |
| Expenses | 15,200 | 15,305 | 12,777 | 8,249 | 6,926 | 8,538 | 8,411 | 8,693 | 10,317 | 12,969 | 12,574 | 12,934 | 12,748 |
| Operating Profit | 686 | 1,900 | 2,096 | 2,097 | 3,344 | 1,799 | 1,945 | 1,506 | 2,305 | 3,820 | 2,847 | 1,953 | 1,947 |
| OPM % | 4% | 11% | 14% | 20% | 33% | 17% | 19% | 15% | 18% | 23% | 18% | 13% | 13% |
| Other Income | -154 | 183 | 210 | 293 | 262 | 785 | 6,480 | 254 | 486 | 218 | -521 | 287 | 285 |
| Interest | 579 | 461 | 525 | 297 | 326 | 354 | 342 | 367 | 303 | 406 | 530 | 563 | 576 |
| Depreciation | 471 | 463 | 526 | 512 | 518 | 568 | 666 | 759 | 806 | 892 | 980 | 1,123 | 1,138 |
| Profit before tax | -519 | 1,159 | 1,255 | 1,580 | 2,763 | 1,661 | 7,416 | 634 | 1,682 | 2,740 | 816 | 554 | 518 |
| Tax % | 56% | 30% | 20% | 22% | 2% | 17% | 3% | 31% | 16% | 11% | 47% | 30% | |
| Net Profit | -811 | 802 | 1,006 | 1,234 | 2,702 | 1,387 | 7,228 | 436 | 1,405 | 2,434 | 435 | 387 | 400 |
| EPS in Rs | -40.50 | 23.41 | 30.24 | 38.98 | 95.49 | 45.37 | 274.97 | 10.06 | 49.37 | 90.93 | 10.52 | 9.22 | 8.63 |
| Dividend Payout % | -25% | 53% | 33% | 28% | 23% | 28% | 4% | 99% | 25% | 19% | 143% | 119% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 198.89% | 25.44% | 22.66% | 118.96% | -48.67% | 421.12% | -93.97% | 222.25% | 73.24% | -82.13% | -11.03% |
| Change in YoY Net Profit Growth (%) | 0.00% | -173.45% | -2.77% | 96.30% | -167.63% | 469.79% | -515.09% | 316.22% | -149.01% | -155.37% | 71.09% |
Tata Chemicals Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | -1% |
| 5 Years: | 8% |
| 3 Years: | 6% |
| TTM: | -1% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | -8% |
| 5 Years: | -48% |
| 3 Years: | -40% |
| TTM: | -45% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 19% |
| 5 Years: | 25% |
| 3 Years: | -6% |
| 1 Year: | -13% |
| Return on Equity | |
|---|---|
| 10 Years: | 12% |
| 5 Years: | 5% |
| 3 Years: | 5% |
| Last Year: | 1% |
Last Updated: September 5, 2025, 4:00 am
Balance Sheet
Last Updated: December 4, 2025, 1:14 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 255 | 255 | 255 | 255 | 255 | 255 | 255 | 255 | 255 | 255 | 255 | 255 | 255 |
| Reserves | 5,311 | 5,297 | 6,600 | 7,653 | 10,847 | 12,086 | 12,643 | 14,035 | 17,998 | 19,466 | 21,986 | 21,339 | 22,103 |
| Borrowings | 8,393 | 8,379 | 9,090 | 7,072 | 6,108 | 6,130 | 7,702 | 6,933 | 7,024 | 6,296 | 5,563 | 7,072 | 7,495 |
| Other Liabilities | 6,127 | 6,872 | 8,402 | 8,607 | 8,648 | 8,398 | 7,073 | 7,115 | 8,566 | 8,923 | 8,907 | 9,084 | 9,002 |
| Total Liabilities | 20,086 | 20,802 | 24,346 | 23,587 | 25,858 | 26,869 | 27,673 | 28,337 | 33,843 | 34,940 | 36,711 | 37,750 | 38,855 |
| Fixed Assets | 11,007 | 11,359 | 13,431 | 12,644 | 12,787 | 13,551 | 15,356 | 15,261 | 16,044 | 17,092 | 17,861 | 19,600 | 20,171 |
| CWIP | 468 | 189 | 350 | 333 | 409 | 774 | 835 | 1,094 | 1,668 | 2,410 | 2,217 | 1,913 | 2,099 |
| Investments | 441 | 443 | 2,188 | 2,787 | 2,840 | 5,615 | 4,285 | 5,816 | 7,683 | 7,448 | 9,739 | 9,144 | 9,555 |
| Other Assets | 8,171 | 8,811 | 8,377 | 7,822 | 9,822 | 6,929 | 7,198 | 6,167 | 8,448 | 7,990 | 6,894 | 7,093 | 7,030 |
| Total Assets | 20,086 | 20,802 | 24,346 | 23,587 | 25,858 | 26,869 | 27,673 | 28,337 | 33,843 | 34,940 | 36,711 | 37,750 | 38,855 |
Below is a detailed analysis of the balance sheet data for Tata Chemicals Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 255.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 255.00 Cr..
- For Reserves, as of Sep 2025, the value is 22,103.00 Cr.. The value appears strong and on an upward trend. It has increased from 21,339.00 Cr. (Mar 2025) to 22,103.00 Cr., marking an increase of 764.00 Cr..
- For Borrowings, as of Sep 2025, the value is 7,495.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 7,072.00 Cr. (Mar 2025) to 7,495.00 Cr., marking an increase of 423.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 9,002.00 Cr.. The value appears to be improving (decreasing). It has decreased from 9,084.00 Cr. (Mar 2025) to 9,002.00 Cr., marking a decrease of 82.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 38,855.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 37,750.00 Cr. (Mar 2025) to 38,855.00 Cr., marking an increase of 1,105.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 20,171.00 Cr.. The value appears strong and on an upward trend. It has increased from 19,600.00 Cr. (Mar 2025) to 20,171.00 Cr., marking an increase of 571.00 Cr..
- For CWIP, as of Sep 2025, the value is 2,099.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,913.00 Cr. (Mar 2025) to 2,099.00 Cr., marking an increase of 186.00 Cr..
- For Investments, as of Sep 2025, the value is 9,555.00 Cr.. The value appears strong and on an upward trend. It has increased from 9,144.00 Cr. (Mar 2025) to 9,555.00 Cr., marking an increase of 411.00 Cr..
- For Other Assets, as of Sep 2025, the value is 7,030.00 Cr.. The value appears to be declining and may need further review. It has decreased from 7,093.00 Cr. (Mar 2025) to 7,030.00 Cr., marking a decrease of 63.00 Cr..
- For Total Assets, as of Sep 2025, the value is 38,855.00 Cr.. The value appears strong and on an upward trend. It has increased from 37,750.00 Cr. (Mar 2025) to 38,855.00 Cr., marking an increase of 1,105.00 Cr..
Notably, the Reserves (22,103.00 Cr.) exceed the Borrowings (7,495.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 678.00 | -7.00 | -7.00 | -5.00 | -3.00 | -5.00 | -6.00 | -5.00 | -5.00 | -3.00 | -3.00 | -6.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 74 | 73 | 88 | 74 | 46 | 51 | 56 | 50 | 56 | 57 | 45 | 47 |
| Inventory Days | 96 | 137 | 119 | 244 | 304 | 315 | 347 | 257 | 318 | 282 | 341 | 324 |
| Days Payable | 119 | 138 | 99 | 232 | 307 | 269 | 302 | 256 | 338 | 289 | 320 | 318 |
| Cash Conversion Cycle | 52 | 72 | 107 | 86 | 43 | 97 | 100 | 51 | 35 | 50 | 66 | 53 |
| Working Capital Days | 11 | -4 | 31 | -4 | 27 | -2 | -102 | 27 | -29 | 29 | -22 | -21 |
| ROCE % | 3% | 11% | 11% | 10% | 16% | 9% | 36% | 4% | 8% | 12% | 8% | 4% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Kotak Flexicap Fund | 3,750,000 | 0.51 | 287.08 | N/A | N/A | N/A |
| ICICI Prudential Value Fund | 3,706,957 | 0.46 | 283.79 | 2,843,828 | 2026-01-26 02:31:34 | 30.35% |
| ICICI Prudential India Opportunities Fund | 2,879,270 | 0.63 | 220.42 | N/A | N/A | N/A |
| ICICI Prudential Multicap Fund | 2,584,831 | 1.22 | 197.88 | N/A | N/A | N/A |
| ICICI Prudential Smallcap Fund | 2,320,406 | 2.11 | 177.64 | 2,300,000 | 2025-12-15 00:52:54 | 0.89% |
| Kotak Large & Midcap Fund | 2,064,884 | 0.53 | 158.08 | N/A | N/A | N/A |
| ICICI Prudential Multi Asset Fund | 1,137,376 | 0.11 | 87.07 | N/A | N/A | N/A |
| HDFC Large and Mid Cap Fund | 868,808 | 0.23 | 66.51 | N/A | N/A | N/A |
| Kotak Multi Asset Allocation Fund | 700,000 | 0.49 | 53.59 | N/A | N/A | N/A |
| Tata Ethical Fund | 652,838 | 1.31 | 49.98 | N/A | N/A | N/A |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 9.23 | 10.52 | 90.95 | 49.37 | 10.06 |
| Diluted EPS (Rs.) | 9.23 | 10.52 | 90.95 | 49.37 | 10.06 |
| Cash EPS (Rs.) | 53.18 | 52.82 | 130.43 | 77.91 | 45.91 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 846.82 | 906.43 | 809.49 | 751.80 | 594.25 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 846.82 | 906.43 | 809.49 | 751.80 | 594.25 |
| Revenue From Operations / Share (Rs.) | 583.80 | 604.75 | 658.39 | 495.33 | 400.27 |
| PBDIT / Share (Rs.) | 85.41 | 122.86 | 158.43 | 100.49 | 68.09 |
| PBIT / Share (Rs.) | 41.37 | 84.43 | 123.45 | 68.85 | 38.29 |
| PBT / Share (Rs.) | 14.39 | 29.88 | 107.45 | 56.53 | 23.87 |
| Net Profit / Share (Rs.) | 9.14 | 14.39 | 95.45 | 46.27 | 16.11 |
| NP After MI And SOA / Share (Rs.) | 9.21 | 10.51 | 90.86 | 49.35 | 10.06 |
| PBDIT Margin (%) | 14.63 | 20.31 | 24.06 | 20.28 | 17.01 |
| PBIT Margin (%) | 7.08 | 13.96 | 18.75 | 13.90 | 9.56 |
| PBT Margin (%) | 2.46 | 4.94 | 16.32 | 11.41 | 5.96 |
| Net Profit Margin (%) | 1.56 | 2.37 | 14.49 | 9.34 | 4.02 |
| NP After MI And SOA Margin (%) | 1.57 | 1.73 | 13.80 | 9.96 | 2.51 |
| Return on Networth / Equity (%) | 1.08 | 1.20 | 11.74 | 6.88 | 1.79 |
| Return on Capital Employeed (%) | 3.33 | 7.01 | 10.43 | 6.55 | 4.08 |
| Return On Assets (%) | 0.62 | 0.72 | 6.60 | 3.71 | 0.90 |
| Long Term Debt / Equity (X) | 0.19 | 0.13 | 0.28 | 0.20 | 0.36 |
| Total Debt / Equity (X) | 0.29 | 0.22 | 0.30 | 0.37 | 0.38 |
| Asset Turnover Ratio (%) | 0.39 | 0.42 | 0.48 | 0.40 | 0.14 |
| Current Ratio (X) | 1.09 | 1.05 | 1.66 | 1.23 | 1.49 |
| Quick Ratio (X) | 0.67 | 0.63 | 1.15 | 0.90 | 1.11 |
| Inventory Turnover Ratio (X) | 1.01 | 1.07 | 1.22 | 1.22 | 0.50 |
| Dividend Payout Ratio (NP) (%) | 162.55 | 166.41 | 13.72 | 20.25 | 109.30 |
| Dividend Payout Ratio (CP) (%) | 28.12 | 35.73 | 9.90 | 12.34 | 27.59 |
| Earning Retention Ratio (%) | -62.55 | -66.41 | 86.28 | 79.75 | -9.30 |
| Cash Earning Retention Ratio (%) | 71.88 | 64.27 | 90.10 | 87.66 | 72.41 |
| Interest Coverage Ratio (X) | 3.87 | 5.91 | 9.95 | 8.46 | 4.72 |
| Interest Coverage Ratio (Post Tax) (X) | 1.58 | 3.34 | 7.04 | 4.91 | 2.12 |
| Enterprise Value (Cr.) | 28656.05 | 32847.30 | 31130.10 | 31228.96 | 24062.00 |
| EV / Net Operating Revenue (X) | 1.92 | 2.13 | 1.85 | 2.47 | 2.36 |
| EV / EBITDA (X) | 13.16 | 10.48 | 7.71 | 12.20 | 13.87 |
| MarketCap / Net Operating Revenue (X) | 1.48 | 1.79 | 1.48 | 1.97 | 1.88 |
| Retention Ratios (%) | -62.55 | -66.41 | 86.27 | 79.74 | -9.30 |
| Price / BV (X) | 1.02 | 1.24 | 1.26 | 1.36 | 1.34 |
| Price / Net Operating Revenue (X) | 1.48 | 1.79 | 1.48 | 1.97 | 1.88 |
| EarningsYield | 0.01 | 0.01 | 0.09 | 0.05 | 0.01 |
After reviewing the key financial ratios for Tata Chemicals Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 9.23. This value is within the healthy range. It has decreased from 10.52 (Mar 24) to 9.23, marking a decrease of 1.29.
- For Diluted EPS (Rs.), as of Mar 25, the value is 9.23. This value is within the healthy range. It has decreased from 10.52 (Mar 24) to 9.23, marking a decrease of 1.29.
- For Cash EPS (Rs.), as of Mar 25, the value is 53.18. This value is within the healthy range. It has increased from 52.82 (Mar 24) to 53.18, marking an increase of 0.36.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 846.82. It has decreased from 906.43 (Mar 24) to 846.82, marking a decrease of 59.61.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 846.82. It has decreased from 906.43 (Mar 24) to 846.82, marking a decrease of 59.61.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 583.80. It has decreased from 604.75 (Mar 24) to 583.80, marking a decrease of 20.95.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 85.41. This value is within the healthy range. It has decreased from 122.86 (Mar 24) to 85.41, marking a decrease of 37.45.
- For PBIT / Share (Rs.), as of Mar 25, the value is 41.37. This value is within the healthy range. It has decreased from 84.43 (Mar 24) to 41.37, marking a decrease of 43.06.
- For PBT / Share (Rs.), as of Mar 25, the value is 14.39. This value is within the healthy range. It has decreased from 29.88 (Mar 24) to 14.39, marking a decrease of 15.49.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 9.14. This value is within the healthy range. It has decreased from 14.39 (Mar 24) to 9.14, marking a decrease of 5.25.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 9.21. This value is within the healthy range. It has decreased from 10.51 (Mar 24) to 9.21, marking a decrease of 1.30.
- For PBDIT Margin (%), as of Mar 25, the value is 14.63. This value is within the healthy range. It has decreased from 20.31 (Mar 24) to 14.63, marking a decrease of 5.68.
- For PBIT Margin (%), as of Mar 25, the value is 7.08. This value is below the healthy minimum of 10. It has decreased from 13.96 (Mar 24) to 7.08, marking a decrease of 6.88.
- For PBT Margin (%), as of Mar 25, the value is 2.46. This value is below the healthy minimum of 10. It has decreased from 4.94 (Mar 24) to 2.46, marking a decrease of 2.48.
- For Net Profit Margin (%), as of Mar 25, the value is 1.56. This value is below the healthy minimum of 5. It has decreased from 2.37 (Mar 24) to 1.56, marking a decrease of 0.81.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 1.57. This value is below the healthy minimum of 8. It has decreased from 1.73 (Mar 24) to 1.57, marking a decrease of 0.16.
- For Return on Networth / Equity (%), as of Mar 25, the value is 1.08. This value is below the healthy minimum of 15. It has decreased from 1.20 (Mar 24) to 1.08, marking a decrease of 0.12.
- For Return on Capital Employeed (%), as of Mar 25, the value is 3.33. This value is below the healthy minimum of 10. It has decreased from 7.01 (Mar 24) to 3.33, marking a decrease of 3.68.
- For Return On Assets (%), as of Mar 25, the value is 0.62. This value is below the healthy minimum of 5. It has decreased from 0.72 (Mar 24) to 0.62, marking a decrease of 0.10.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.19. This value is below the healthy minimum of 0.2. It has increased from 0.13 (Mar 24) to 0.19, marking an increase of 0.06.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.29. This value is within the healthy range. It has increased from 0.22 (Mar 24) to 0.29, marking an increase of 0.07.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.39. It has decreased from 0.42 (Mar 24) to 0.39, marking a decrease of 0.03.
- For Current Ratio (X), as of Mar 25, the value is 1.09. This value is below the healthy minimum of 1.5. It has increased from 1.05 (Mar 24) to 1.09, marking an increase of 0.04.
- For Quick Ratio (X), as of Mar 25, the value is 0.67. This value is below the healthy minimum of 1. It has increased from 0.63 (Mar 24) to 0.67, marking an increase of 0.04.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 1.01. This value is below the healthy minimum of 4. It has decreased from 1.07 (Mar 24) to 1.01, marking a decrease of 0.06.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 162.55. This value exceeds the healthy maximum of 50. It has decreased from 166.41 (Mar 24) to 162.55, marking a decrease of 3.86.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 28.12. This value is within the healthy range. It has decreased from 35.73 (Mar 24) to 28.12, marking a decrease of 7.61.
- For Earning Retention Ratio (%), as of Mar 25, the value is -62.55. This value is below the healthy minimum of 40. It has increased from -66.41 (Mar 24) to -62.55, marking an increase of 3.86.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 71.88. This value exceeds the healthy maximum of 70. It has increased from 64.27 (Mar 24) to 71.88, marking an increase of 7.61.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 3.87. This value is within the healthy range. It has decreased from 5.91 (Mar 24) to 3.87, marking a decrease of 2.04.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 1.58. This value is below the healthy minimum of 3. It has decreased from 3.34 (Mar 24) to 1.58, marking a decrease of 1.76.
- For Enterprise Value (Cr.), as of Mar 25, the value is 28,656.05. It has decreased from 32,847.30 (Mar 24) to 28,656.05, marking a decrease of 4,191.25.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.92. This value is within the healthy range. It has decreased from 2.13 (Mar 24) to 1.92, marking a decrease of 0.21.
- For EV / EBITDA (X), as of Mar 25, the value is 13.16. This value is within the healthy range. It has increased from 10.48 (Mar 24) to 13.16, marking an increase of 2.68.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.48. This value is within the healthy range. It has decreased from 1.79 (Mar 24) to 1.48, marking a decrease of 0.31.
- For Retention Ratios (%), as of Mar 25, the value is -62.55. This value is below the healthy minimum of 30. It has increased from -66.41 (Mar 24) to -62.55, marking an increase of 3.86.
- For Price / BV (X), as of Mar 25, the value is 1.02. This value is within the healthy range. It has decreased from 1.24 (Mar 24) to 1.02, marking a decrease of 0.22.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.48. This value is within the healthy range. It has decreased from 1.79 (Mar 24) to 1.48, marking a decrease of 0.31.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Tata Chemicals Ltd:
- Net Profit Margin: 1.56%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 3.33% (Industry Average ROCE: 7.11%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 1.08% (Industry Average ROE: 8.14%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 1.58
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.67
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 65.9 (Industry average Stock P/E: 835.1)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.29
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 1.56%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Chemicals - Inorganic - Caustic Soda/Soda Ash | Bombay House, 24, Homi Mody Street, Mumbai Maharashtra 400001 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. S Padmanabhan | Chairman |
| Mr. R Mukundan | Managing Director & CEO |
| Mr. Modan Saha | Director |
| Mrs. Padmini Khare Kaicker | Independent Director |
| Mr. Rajiv Dube | Independent Director |
| Dr. C V Natraj | Independent Director |
| Mr. K B S Anand | Independent Director |
FAQ
What is the intrinsic value of Tata Chemicals Ltd?
Tata Chemicals Ltd's intrinsic value (as of 07 February 2026) is ₹397.55 which is 43.53% lower the current market price of ₹704.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹17,933 Cr. market cap, FY2025-2026 high/low of ₹1,027/692, reserves of ₹22,103 Cr, and liabilities of ₹38,855 Cr.
What is the Market Cap of Tata Chemicals Ltd?
The Market Cap of Tata Chemicals Ltd is 17,933 Cr..
What is the current Stock Price of Tata Chemicals Ltd as on 07 February 2026?
The current stock price of Tata Chemicals Ltd as on 07 February 2026 is ₹704.
What is the High / Low of Tata Chemicals Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Tata Chemicals Ltd stocks is ₹1,027/692.
What is the Stock P/E of Tata Chemicals Ltd?
The Stock P/E of Tata Chemicals Ltd is 65.9.
What is the Book Value of Tata Chemicals Ltd?
The Book Value of Tata Chemicals Ltd is 877.
What is the Dividend Yield of Tata Chemicals Ltd?
The Dividend Yield of Tata Chemicals Ltd is 1.56 %.
What is the ROCE of Tata Chemicals Ltd?
The ROCE of Tata Chemicals Ltd is 3.96 %.
What is the ROE of Tata Chemicals Ltd?
The ROE of Tata Chemicals Ltd is 1.20 %.
What is the Face Value of Tata Chemicals Ltd?
The Face Value of Tata Chemicals Ltd is 10.0.